WO2009007675A3 - Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist - Google Patents
Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist Download PDFInfo
- Publication number
- WO2009007675A3 WO2009007675A3 PCT/GB2008/002201 GB2008002201W WO2009007675A3 WO 2009007675 A3 WO2009007675 A3 WO 2009007675A3 GB 2008002201 W GB2008002201 W GB 2008002201W WO 2009007675 A3 WO2009007675 A3 WO 2009007675A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- atherosclerosis
- antagonist
- mast cell
- gamma
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
There is provided combination products comprising (a) a mast cell inhibitor, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a P2Y12 antagonist, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in atherosclerosis and related conditions.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92973207P | 2007-07-11 | 2007-07-11 | |
US92972907P | 2007-07-11 | 2007-07-11 | |
US60/929,732 | 2007-07-11 | ||
US60/929,729 | 2007-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009007675A2 WO2009007675A2 (en) | 2009-01-15 |
WO2009007675A3 true WO2009007675A3 (en) | 2009-03-12 |
Family
ID=39769186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/002201 WO2009007675A2 (en) | 2007-07-11 | 2008-06-25 | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009007675A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA100864C2 (en) * | 2007-12-03 | 2013-02-11 | Астразенека Аб | Method for the for the treatment or prevention of abdominal aortic aneurysms |
JP2012528844A (en) * | 2009-06-01 | 2012-11-15 | バイオコピア リミテッド | Use of amlexanox in the treatment of diseases caused by neutrophils |
WO2011065444A1 (en) * | 2009-11-27 | 2011-06-03 | 学校法人東海大学 | Antithrombotic agent |
EP2515871B1 (en) * | 2009-12-23 | 2015-09-23 | ratiopharm GmbH | Solid pharmaceutical dosage form of ticagrelor |
EP2377520A1 (en) * | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Pharmaceutical compound of prasugrel |
GB201601138D0 (en) * | 2016-01-21 | 2016-03-09 | Rspr Pharma Ab | New use |
CN109646442B (en) * | 2019-01-29 | 2023-01-24 | 军事科学院军事医学研究院生物医学分析中心 | Application of acetate compound in preparation of cycloguanosine synthetase acetylation drugs |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086349A (en) * | 1975-07-30 | 1978-04-25 | Mitsubishi Yuka Pharmaceutical Co., Ltd. | Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma |
US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
EP0316174A1 (en) * | 1987-11-10 | 1989-05-17 | Tokyo Tanabe Company Limited | Aqueous preparation of 9-methyl-3-(1H-tetrazol-5-yl)-4H-Pyrido[1,2-a]pyrimidin-4-one potassium salt |
EP0766963A1 (en) * | 1994-05-31 | 1997-04-09 | Tokyo Tanabe Company Limited | Arteriosclerosis depressant |
US20020103219A1 (en) * | 2000-10-05 | 2002-08-01 | Jeremy Jacob | Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders |
EP1285921A1 (en) * | 2001-08-10 | 2003-02-26 | Dinamite Dipharma S.p.A. | A process for the preparation of high purity pemirolast |
US6585995B1 (en) * | 1999-09-21 | 2003-07-01 | Hanson Stephen R | Methods and compositions for treating platelet-related disorders |
US20050181023A1 (en) * | 2004-02-17 | 2005-08-18 | Young Janel E. | Drug-enhanced adhesion prevention |
WO2005092264A1 (en) * | 2004-03-10 | 2005-10-06 | Ethicon, Inc. | Drug-enhanced adhesion prevention |
WO2007024472A2 (en) * | 2005-08-19 | 2007-03-01 | Eli Lilly And Company | USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES |
-
2008
- 2008-06-25 WO PCT/GB2008/002201 patent/WO2009007675A2/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086349A (en) * | 1975-07-30 | 1978-04-25 | Mitsubishi Yuka Pharmaceutical Co., Ltd. | Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma |
US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
EP0316174A1 (en) * | 1987-11-10 | 1989-05-17 | Tokyo Tanabe Company Limited | Aqueous preparation of 9-methyl-3-(1H-tetrazol-5-yl)-4H-Pyrido[1,2-a]pyrimidin-4-one potassium salt |
EP0766963A1 (en) * | 1994-05-31 | 1997-04-09 | Tokyo Tanabe Company Limited | Arteriosclerosis depressant |
US6585995B1 (en) * | 1999-09-21 | 2003-07-01 | Hanson Stephen R | Methods and compositions for treating platelet-related disorders |
US20020103219A1 (en) * | 2000-10-05 | 2002-08-01 | Jeremy Jacob | Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders |
EP1285921A1 (en) * | 2001-08-10 | 2003-02-26 | Dinamite Dipharma S.p.A. | A process for the preparation of high purity pemirolast |
US20050181023A1 (en) * | 2004-02-17 | 2005-08-18 | Young Janel E. | Drug-enhanced adhesion prevention |
WO2005092264A1 (en) * | 2004-03-10 | 2005-10-06 | Ethicon, Inc. | Drug-enhanced adhesion prevention |
WO2007024472A2 (en) * | 2005-08-19 | 2007-03-01 | Eli Lilly And Company | USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES |
Non-Patent Citations (17)
Title |
---|
"PEMIROLAST POTASSIUM", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 28, no. 1, 1 January 1992 (1992-01-01), pages 29 - 31, XP008066535, ISSN: 0025-7656 * |
ISAJI M ET AL: "TRANILAST INHIBITS THE PROLIFERATION, CHEMOTAXIS AND TUBE FORMATIONOF HUMAN MICROVASCULAR ENDOTHELIAL CELLS IN VITRO AND ANGIOGENESIS IN VIVO", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 122, no. 6, November 1997 (1997-11-01), pages 1061 - 1066, XP000997892, ISSN: 0007-1188 * |
JONES N L ET AL: "Ketotifen therapy for acute ulcerative colitis in children: A pilot study", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 3, March 1998 (1998-03-01), pages 609 - 615, XP008086243, ISSN: 0163-2116 * |
MARSHALL J K ET AL: "Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance", CANADIAN JOURNAL OF GASTROENTEROLOGY, MEDICARE PUBL., OAKVILLE, CA, vol. 12, no. 4, 1998, pages 273 - 275, XP008086245, ISSN: 0835-7900 * |
MATSUMURA ET AL: "Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast", MEDLINE, 23 February 1999 (1999-02-23), XP002953929 * |
MINOCHA A ET AL: "Role of ketotifen in pathogenesis of chronic ulcerative colitis", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 104, no. 4 SUPPL, 1993, pages A746, XP008086242, ISSN: 0016-5085 * |
NOBUHIDE O ET AL: "Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 56, no. 4, April 2007 (2007-04-01), pages 599 - 600, XP008086231, ISSN: 0017-5749 * |
SAIURA A ET AL: "Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 433, no. 2-3, 21 December 2001 (2001-12-21), pages 163 - 168, XP008086230, ISSN: 0014-2999 * |
SHIMIZU T ET AL: "INHIBITORY EFFECTS OF AZELASTINE AND TRANILAST ON LEUKOTRIENE B4 AND LEUKOTRIENE C4, GENERATION BY RAT COLONIC MUCOSA", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 53, no. 5, 1995, pages 355 - 358, XP001042184, ISSN: 0952-3278 * |
STILLER-MATULA J ET AL: "Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 97, no. 3, March 2007 (2007-03-01), pages 385 - 393, XP008086107, ISSN: 0340-6245 * |
SUWAKI T ET AL: "Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 1, no. 12, November 2001 (2001-11-01), pages 2163 - 2171, XP002443957, ISSN: 1567-5769 * |
TAMAOKI JUN: "Role of a Th2 cytokine inhibitor in asthma treatment", ALLERGOLOGY INTERNATIONAL, BLACKWELL SCIENCE, CARLTON,, AU, vol. 53, no. 2, June 2004 (2004-06-01), pages 55 - 60, XP002443956, ISSN: 1323-8930 * |
TEH L G ET AL: "Does the addition of ketotifen to non-steroidal anti-inflammatory drugs confer any additional benefit in rheumatoid arthritis?", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 17, no. 2, 1984, pages 157 - 159, XP008086082, ISSN: 0306-5251 * |
WALLENTIN L C ET AL: "Prasugrel (CS-747), a novel thienopyridine P2Y12 receptor antagonist, results in more effective platelet inhibition than clopidogrel in aspirin-treated patients with atherosclerotic disease", EUROPEAN HEART JOURNAL, THE EUROPEAN SOCIETY OF CARDIOLOGY, XX, vol. 26, no. Suppl1, 6 September 2005 (2005-09-06), pages 488, XP008086116, ISSN: 0195-668X * |
YAMADA N ET AL: "MY-1250, a major metabolite of the anti-allergic drug repirinast, induces phosphorylation of a 78-kDa protein in rat mast cells", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 44, no. 6, 25 September 1992 (1992-09-25), pages 1211 - 1213, XP023732179, ISSN: 0006-2952, [retrieved on 19920925] * |
YANAGIHARA Y ET AL: "Immunopharmacological studies on TBX, a new antiallergic drug. (4) Effects on type II to IV allergic reactions and immunological functions in animal models", JAPANESE JOURNAL OF PHARMACOLOGY, JPTHE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, vol. 51, no. 1, 1 January 1989 (1989-01-01), pages 93 - 100, XP008066536, ISSN: 0021-5198 * |
ZHANG W ET AL: "Development of new therapeutic effect and mechanism of tranilast", ZHONGGUO XIN YAO YU LINCHUANG ZAZHI - CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES, SHANGHAI SHI YIYAO GUANLIJU KE-JI QINGBAO YANJIUSUO ZHONGGUO, CN, vol. 23, no. 11, November 2004 (2004-11-01), pages 795 - 798, XP008086232, ISSN: 1007-7669 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009007675A2 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009007673A3 (en) | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist | |
WO2009007675A3 (en) | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist | |
EP2497470B8 (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
PT2050749T (en) | Pyrimidine derivative as pi3k inhibitor and use thereof | |
EP1663210A4 (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
EP2223921B8 (en) | 2-Thiophen-2-yl-oxazole, 2-Thiophen-2-yl-thiazole and 2-Thiophen-2-yl-1H-imidazole derivatives as antiviral agents | |
SI1910348T1 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
IL192603A0 (en) | Thieno-pyridine derivatives as mek inhibitors | |
EP2386184A4 (en) | Random access scheme for preventing unnecessary retransmission and user equipment for the same | |
EP2038775A4 (en) | Visual and multi-dimensional search | |
PT1928840E (en) | 1h-pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors | |
TWI316258B (en) | Adjustable delay cells and delay lines including the same | |
IL185724A0 (en) | Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor | |
AU2006321904A8 (en) | 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors | |
EP1924606A4 (en) | Devices, compositions and methods for the protection and repair of cells and tissues | |
WO2009007679A3 (en) | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist | |
WO2009007674A3 (en) | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast | |
MX2009006507A (en) | New combination for use in the treatment of inflammatory disorders. | |
IL201168A0 (en) | New combination for use in the treatment of inflammatory disorders | |
WO2009007680A3 (en) | Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders | |
GB0502669D0 (en) | Swivel laptop/utility table | |
WO2007035964A3 (en) | Vigabatrin bioisoteres and related methods of use | |
AU2005100666A4 (en) | Laptop stable table | |
张艳 | Water-saving | |
AU2005100796A4 (en) | Hexagonal Rotating Pool Table |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08762504 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08762504 Country of ref document: EP Kind code of ref document: A2 |